WALTHAM, Mass. , Aug. 23, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4 - 6, 2018, at The St. Regis New York in New York City. Shai N. Gozani, M.D., Ph.D.,

Presentation Shifted to 10:00 am on September 6, 2018 WALTHAM, Mass. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) reported that the time previously announced for its presentation at the H.C.Wainwright 20th Annual Global Investment Conference has been shifted to 10:00 am

WALTHAM, Mass. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it will present three scientific posters at the upcoming PAINWeek 2018 National Pain Conference to be held in Las Vegas, NV, September 4-8. The PAINWeek 2018 Abstract Book may be accessed here

WALTHAM, Mass. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported that it will be both exhibiting and sponsoring a diabetic neuropathy symposium at the 28th Annual Meeting of NEURODIAB held in Rome, Italy September 4-7 .

Company will launch its latest innovation at national conference on pain management LAS VEGAS , Sept. 4, 2018 /PRNewswire/ -- Tomorrow at PAINWeek 2018, NeuroMetrix Inc. (Nasdaq: NURO) , will unveil its latest breakthrough for the treatment of chronic pain.

WALTHAM, Mass. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), reported that its President and CEO, Dr. Shai N. Gozani , yesterday participated in a discussion of the opioid crisis and the Company’s Quell ® Wearable Pain Relief Technology™ on Mornings with Maria on the Fox

WALTHAM, Mass. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today announced that it will showcase its latest product innovation, Quell ® 2.0 Wearable Pain Relief Technology™, during a workshop at DTxDM East, and will discuss using real world, patient generated data to

WALTHAM, Mass. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of a clinical study of Quell ® wearable pain relief in the Journal of Pain and Relief.  The paper is titled “Real-World Evidence for the Widespread Effects of Fixed-Site High Frequency

WALTHAM, Mass. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2018 third quarter financial results before the opening of the market on Wednesday, October 17, 2018. The Company will host a conference call at 8:00 a.m., Eastern

$3.8M GSK Milestone; Improved Operating Performance WALTHAM, Mass. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2018 . The Company develops and markets novel therapies for chronic health